For the Inventor, By the Inventor

Enter assignee name

Abivax

Calculating rank

USPTO Granted Patents = 40

% Expired Patents = 5.0

CIPO Patents = 2

EPO Patents = 26

Trademarks = 1

Forward Citations = 151

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Didier Scherrer (36 out of 36 patents)

Jamal Tazi (34 out of 40 patents)

Romain Najman (31 out of 31 patents)

4. Florence Mahuteau (23 out of 23 patents)

5. Aude Garcel (11 out of 11 patents)

6. Julien Santo (9 out of 9 patents)

7. Pierre Roux (8 out of 17 patents)

8. Noelie Campos (7 out of 7 patents)

9. Gilles Gadea (6 out of 10 patents)

10. Carsten Brock (6 out of 6 patents)

11. Nathalie Cahuzac (6 out of 6 patents)

12. Cécile Apolit (6 out of 6 patents)

13. Philippe Pouletty (5 out of 10 patents)

14. Florence Mahuteau-Betzer (4 out of 9 patents)

15. Florence Mahuteau-betzer (4 out of 4 patents)

Core Competencies:

Quinoline Derivatives

RNA Virus Infection

Cancer Treatment

Inflammatory Diseases

Therapeutic Agents

Biomarkers

Vaccine Composition

ABX196

AIDS Treatment

Alpha Galactosyl Ceramides

Screening Methods

P53 Expression

40 patents: Sort by Forward Citations

1. 12767994 - BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER (2026-10-20),

2. 12617756 - Substituted imidazolidines for treating a RNA virus infection (2026-05-05),

3. 12479802 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2025-11-25),

4. 12421206 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-09-23),

5. 12247018 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-03-11),

6. 12202804 - In vitro or ex vivo methods for screening a quinoline derivative (2025-01-21),

7. 12084422 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2024-09-10),

8. 11992499 - Quinoline derivatives for use in the treatment of inflammation diseases (2024-05-28),

9. 11826372 - Combinations including ABX196 for the treatment of cancer (2023-11-28),

10. 11739073 - Aryl-n-aryl derivatives for treating a RNA virus infection (2023-08-29),

11. 11649211 - Use of quinoline derivatives for the treatment of inflammatory diseases (2023-05-16),

12. 11649210 - Use of quinoline derivatives for the treatment of inflammatory diseases (2023-05-16),

13. 11441181 - miRNA-124 as a biomarker (2022-09-13),

14. 11427566 - Compounds useful for treating cancer (2022-08-30),

15. 11278552 - Combinations including ABX196 for the treatment of cancer (2022-03-22),

Company Overview

Abivax is a biopharmaceutical company based in Paris, France, focused on developing innovative therapies for inflammatory diseases and viral infections. The company specializes in the research and development of novel drug candidates, leveraging its proprietary technology platforms to address unmet medical needs. Abivax aims to improve patient outcomes through its commitment to advancing therapeutic solutions that target complex diseases, with a strong emphasis on scientific rigor and clinical efficacy.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

40 Patents

#151 in Paris

#570 in France

#17,087 in the World

Abivax

Forward Citations = 151

29 inventors:

Didier Scherrer (36 out of 36 patents)

Jamal Tazi (34 out of 40 patents)

Romain Najman (31 out of 31 patents)

4. Florence Mahuteau (23 out of 23 patents)

5. Aude Garcel (11 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Abivax. Retrieved from https://idiyas.com/company/abivax

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…